CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
REVENUES:
Total revenues	$ 461,097	$ 391,706	$ 1,249,605	$ 1,137,998
OPERATING EXPENSES:
Cost of sales	96,949	78,893	263,567	240,245
Research and development	172,963	161,408	542,195	520,938
Selling, general and administrative	170,112	148,566	493,024	440,182
Intangible asset amortization and contingent consideration	17,063	18,580	57,114	42,009
Gain on sale of intangible assets	0	0	(15,000)	(20,000)
Total operating expenses	457,087	407,447	1,340,900	1,223,374
INCOME (LOSS) FROM OPERATIONS	4,010	(15,741)	(91,295)	(85,376)
Equity in the loss of BioMarin/Genzyme LLC	(551)	(468)	(780)	(507)
Interest income	5,340	6,338	17,537	17,141
Interest expense	(2,937)	(12,131)	(16,530)	(35,918)
Other income, net	3,960	2,589	6,038	5,266
INCOME (LOSS) BEFORE INCOME TAXES	9,822	(19,413)	(85,030)	(99,394)
Benefit from income taxes	(45,214)	(6,793)	(46,158)	(25,833)
NET INCOME (LOSS)	$ 55,036	$ (12,620)	$ (38,872)	$ (73,561)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)	$ 0.31	$ (0.07)	$ (0.22)	$ (0.42)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)	$ 0.30	$ (0.07)	$ (0.22)	$ (0.42)
Weighted average common shares outstanding, basic (in shares)	179,289	177,481	178,873	176,767
Weighted average common shares outstanding, diluted (in shares)	185,924	177,481	178,873	176,767
COMPREHENSIVE INCOME (LOSS)	$ 74,600	$ (13,651)	$ (7,140)	$ (52,174)
Net product revenues
REVENUES:
Total revenues	450,900	386,320	1,224,458	1,123,205
Royalty and other revenues
REVENUES:
Total revenues	$ 10,197	$ 5,386	$ 25,147	$ 14,793